Business Context and Reporting Period
This Form 8-K was filed by Brilliant Acquisition Corporation, although the request metadata identifies T3 Defense Inc. The report covers events beginning April 20, 2023, with related actions on April 21, 2023. Brilliant is a special purpose acquisition company pursuing a proposed business combination with Nukkleus, Inc.; upon completion, Merger Sub would merge into Brilliant and Brilliant would become a wholly owned subsidiary of Nukkleus.
Key Financial Metrics, Debt, and Liquidity
- Brilliant issued Nukkleus an unsecured, non-interest-bearing promissory note with principal of $32,450 dated April 20, 2023.
- The note matures upon closing of the initial business combination. If no business combination is completed, repayment is limited to amounts remaining outside the trust account, if any.
- Note proceeds were deposited into the trust account in connection with extending the business-combination deadline.
- After redemptions of 258 public shares and the reported contribution, the trust account held approximately $4.47 million, or approximately $11.02 per public share.
- Following the redemptions, Brilliant had 1,816,475 ordinary shares outstanding, including 1,411,000 shares held by initial shareholders that were not subject to redemption.
- The filing does not provide revenue, operating profit, net income, cash-flow, or margin data for the reporting period.
Material Changes Versus the Prior Position
- Shareholders approved extending the business-combination deadline from April 23, 2023 to no later than July 23, 2023.
- The extension may be further extended monthly without additional shareholder approval upon depositing $0.08 per public ordinary share.
- The amended and restated articles of association became effective upon filing with the British Virgin Islands General Registry on April 21, 2023.
- Brilliant separately announced a one-month extension to May 23, 2023, supported by the trust-account contribution and the promissory note.
- At the adjourned shareholder meeting, both the extension proposal and amended-articles proposal received 1,181,812 votes for, 2 against, and no abstentions.
Guidance, Outlook, Risks, and Unusual Items
Management did not provide operating or financial guidance. The principal outlook remains completion of the proposed Nukkleus business combination within the extended deadline. Completion remains subject to applicable closing conditions, including shareholder approvals, minimum trust-account requirements after redemptions, and governmental or regulatory approvals.
- The transaction may not close by the applicable deadline or may not close at all.
- Further extensions may require the stated monthly contribution, and failure to obtain or fund an extension could result in liquidation or other adverse consequences.
- Additional shareholder redemptions could reduce funds available to the combined company and affect satisfaction of minimum trust-account conditions.
- Other cited risks include regulatory and legal proceedings, Nasdaq listing requirements, volatility in the parties’ securities, changes in law, employee-retention issues, and challenges implementing post-transaction business plans.
- The promissory note is an unusual financing obligation because it is unsecured, interest-free, and has limited repayment prospects if the business combination is not completed.
Most Important Facts to Verify
- Verify the applicable issuer: the supplied filing is for Brilliant Acquisition Corporation, not T3 Defense Inc.
- Confirm the current business-combination deadline and whether any additional monthly extensions were obtained after May 23, 2023.
- Review the full promissory note for repayment terms and confirm whether it was repaid, converted, or remained outstanding.
- Reconcile the approximately $4.47 million trust balance and $11.02 per-public-share amount against subsequent filings and redemption activity.
- Review the Nukkleus Form S-4, proxy statement/prospectus, and later SEC filings for transaction status, required approvals, minimum-cash conditions, and updated risk disclosures.